Get the Stockscreener App
0.85
9.84%
-0.0928
After Hours:
.85
Processa Pharmaceuticals Inc stock is traded at $0.85, with a volume of 190.36K.
It is down -9.84% in the last 24 hours and down -6.59% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$0.9428
Open:
$0.925
24h Volume:
190.36K
Relative Volume:
0.57
Market Cap:
$2.78M
Revenue:
-
Net Income/Loss:
$-11.53M
P/E Ratio:
-0.5862
EPS:
-1.45
Net Cash Flow:
$-11.12M
1W Performance:
-23.42%
1M Performance:
-6.59%
6M Performance:
-53.30%
1Y Performance:
-99.49%
1-Day Range:
$0.8442
$0.9855
1-Week Range:
$0.8442
$1.10
52-Week Range:
$0.8442
$185.72
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
7380 COCA COLA DRIVE, HANOVER
Compare PCSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.85 | 2.78M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Processa Pharmaceuticals stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $0.85 - Investing.com
Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics - The Globe and Mail
What is HC Wainwright’s Forecast for PCSA FY2024 Earnings? - Defense World
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Processa Pharmaceuticals stock hits 52-week low at $1.04 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $1.04 - Investing.com India
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Processa Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Processa Pharmaceuticals stock hits 52-week low at $1.18 - Investing.com
Processa Pharmaceuticals stock hits 52-week low at $1.18 By Investing.com - Investing.com UK
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results - The Manila Times
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail
Gastroparesis Treatment Market Size, Demand, Trends, Analysis - openPR
processa pharmaceuticals inc. Earnings dates - RTTNews
Analytical Lens: Exploring Processa Pharmaceuticals Inc (PCSA)’s Financial Story Through Ratios - The Dwinnex
Processa stock rallies 35% post-market on Phase 2 study update - MSN
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer - ForexTV.com
Constellation Brands, Levi Strauss And 3 Stocks To Watch Heading Into Thursday - Benzinga
Pure Storage, Inc. (NYSE:PSTG) CRO Sells $450,709.65 in Stock - Defense World
Peraso Inc’s latest rating changes from various analysts - Knox Daily
Progress Software (PRGS) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Progress Software Stock Jumps On Q3 Earnings: Revenue Beat, EPS Beat, Raised Guidance And More - TradingView
Progress Software Corp (PRGS) Q3 2024 Earnings: EPS of $0.65 Bea - GuruFocus.com
Perrigo shares downgraded amid restructuring efforts - Investing.com India
Jefferies Financial Group Boosts Pacira BioSciences (NASDAQ:PCRX) Price Target to $18.00 - Defense World
A Look at Pacira BioSciences Inc (PCRX) Shares in the Recent Past Indicates Growth - SETE News
Check out these key findings about Privia Health Group Inc (PRVA) - SETE News
Sagefield Capital LP Acquires 1,023,527 Shares of Permian Resources Co. (NASDAQ:PR) - Defense World
Precigen Inc (PGEN)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Monitoring Perrigo Company plc (PRGO) after recent insider movements - Knox Daily
Pacira price target raised to $18 from $15 at Jefferies - TipRanks
Get in on PureCycle Technologies Inc’s (PCT) buy-in window today! - SETE News
72,064 Shares in Primoris Services Co. (NASDAQ:PRIM) Acquired by Appian Way Asset Management LP - MarketBeat
Financial Snapshot: Analyzing PureCycle Technologies Inc (PCT)’s Key Ratio Metrics - The Dwinnex
Primoris Services Co. (NASDAQ:PRIM) Shares Sold by Paradigm Capital Management Inc. NY - Defense World
Dimensional Fund Advisors LP Has $108.58 Million Position in Perdoceo Education Co. (NASDAQ:PRDO) - Defense World
Rs 5,890 Crore Order Book: Construction Company Secures Orders Worth Rs 554.92 Crore, FY25 Order Inflows Reach Rs 1,444.91 Crore – FIIs and DIIs Significantly Increase Stake - Dalal Street Investment Journal
Should We Be Delighted With Poste Italiane S.p.A.'s (BIT:PST) ROE Of 18%? - Simply Wall St
ProSiebenSat.1 Media (OTCMKTS:PBSFY) Shares Up 8.7% - Defense World
Precigen Inc (PGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily
A look into Prothena Corporation plc (PRTA)’s deeper side - SETE News
Understanding the Risks of Investing in Privia Health Group Inc (PRVA) - Knox Daily
Is PureCycle Technologies Inc (PCT) a good investment opportunity? - US Post News
Top Wall Street Forecasters Revamp Progress Software Price Expectations Ahead Of Q3 Earnings - Benzinga
Morse Asset Management Inc Purchases 9,255 Shares of Primoris Services Co. (NASDAQ:PRIM) - MarketBeat
Vanguard Personalized Indexing Management LLC Has $1.19 Million Holdings in POSCO Holdings Inc. (NYSE:PKX) - Defense World
Victory Capital Management Inc. Boosts Stake in Privia Health Group, Inc. (NASDAQ:PRVA) - Defense World
Pacer Advisors Inc. Purchases 518,048 Shares of Perdoceo Education Co. (NASDAQ:PRDO) - MarketBeat
Federated Hermes Inc. Acquires Shares of 43,861 Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Young David | Pres. Research & Development |
Feb 06 '24 |
Buy |
2.53 |
20,000 |
50,504 |
58,387 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 31 '24 |
Buy |
2.37 |
2,500 |
5,925 |
25,978 |
| Lin Patrick | Chief Business - Strategy Off |
Feb 01 '24 |
Buy |
2.40 |
1,500 |
3,600 |
27,478 |
| Ng George K | Chief Executive Officer |
Jan 30 '24 |
Buy |
2.70 |
10,000 |
27,000 |
20,000 |
| Yorke Justin W | Director |
Jan 30 '24 |
Buy |
2.69 |
8,000 |
21,544 |
31,232 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):